Peer-Reviewed Publication
Insights Imaging2025;16(1):224.October 22, 2025Journal Article

White matter lesion effect modification of aspirin and unfractionated heparin during endovascular stroke treatment.

Laura M van Poppel1,2,3,4, Lucas de Vries5,6,7,8,9, Mahsa Mojtahedi5,6,7,8, Henk van Voorst5,6,7,8,10, Praneeta R Konduri5,6,7,8, Rob A van de Graaf11, Wouter van der Steen12, Laura Martou13, Paul Bentley13, Henk A Marquering5,6,7,8, Bart J Emmer5,8, Charles B L M Majoie5,8
1Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands. l.m.vanpoppel@amsterdamumc.nl.
2Department of Biomedical Engineering and Physics, Amsterdam UMC, Amsterdam, The Netherlands. l.m.vanpoppel@amsterdamumc.nl.
3Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. l.m.vanpoppel@amsterdamumc.nl.
4Amsterdam Neuroscience, Amsterdam, The Netherlands. l.m.vanpoppel@amsterdamumc.nl.
5Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
6Department of Biomedical Engineering and Physics, Amsterdam UMC, Amsterdam, The Netherlands.
7Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
8Amsterdam Neuroscience, Amsterdam, The Netherlands.
9Informatics Institute, University of Amsterdam, Amsterdam, The Netherlands.
10Department of Radiology, Stanford University School of Medicine, Palo Alto, CA, USA.
11Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
12Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
13Department of Brain Sciences, Imperial College London, London, UK.

Abstract

OBJECTIVES: Periprocedural aspirin or unfractionated heparin during endovascular treatment in acute ischemic stroke increases symptomatic intracranial hemorrhage (sICH) risk without improving functional outcome. White matter lesions (WMLs) are associated with higher sICH risk and poor functional outcome following stroke. We aimed to assess whether WML volume modifies the effect of aspirin or hepar…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.